Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. [electronic resource]
Producer: 20120816Description: 275-9 p. digitalISSN:- 1715-3360
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Bevacizumab
- Endophthalmitis -- epidemiology
- Female
- Humans
- Intravitreal Injections
- Macular Edema -- drug therapy
- Male
- Middle Aged
- Ranibizumab
- Retinal Detachment -- epidemiology
- Retinal Vein Occlusion -- drug therapy
- Retrospective Studies
- Risk Factors
- Thromboembolism -- epidemiology
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity
- Vitreous Hemorrhage -- epidemiology
- Wet Macular Degeneration -- drug therapy
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.